pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

JANUARY 11, 2021

million price tag. Ibrahim also worked as vice president and global therapeutic head for immuno-oncology at AstraZeneca and MedImmune, helping to develop the immunotherapy Yervoy (ipilimumab) at Bristol-Myers Squibb. Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8

Gene Therapy 58

Gene Therapy Gene Genetic Disease Manufacturing 58

pharmaphorum

JANUARY 5, 2021

Bristol-Myers Squibb’s CLTA4 inhibitor Yervoy (ipilimumab) is already in use for some cancers, including NSCLC in combination with BMS’ PD-1 drug Opdivo (nivolumab), but has been held up by tolerability issues. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52